Literature DB >> 15195000

Sympathetic nervous function in patients with hypertrophic cardiomyopathy assessed by [123I]-MIBG: relationship with left ventricular perfusion and function.

L Pace1, S Betocchi, M A Losi, A M Della Morte, Q Ciampi, R Nugnez, M Chiariello, M Salvatore.   

Abstract

AIM: The aim of the present study was to evaluate [123I] MIBG uptake and clearance in patients with hypertrophic cardiomyopathy (HCM) and to assess their relationships with left ventricular function (systolic and diastolic) and perfusion.
METHODS: Eleven consecutive patients with HCM (8 men and 3 women; mean age 38+/-12 years, none in the dilated phase) underwent (in separate days, in random order) [123I]-MIBG scintigraphy, [(99m)Tc]-MIBI SPET at rest, and echocardiography. All patients were studied in fasting condition, and all medications were discontinued. [(99m)Tc]-MIBI SPET study was performed 1 hour after tracer injection. [123I]-MIBG study was acquired 5 minutes (planar) and 4 hours (planar and SPET) after the i.v. injection of [123I]-MIBG. Heart to mediastinum ratio (H/M) was computed at 4 hours. Wash out rate (WOR) was computed as: (H early - H delayed)/(H early), after decay correction. Both [123I]-MIBG and [(99m)Tc]-MIBI SPET were analyzed on 3 short axis views (apical, middle, and basal). Left ventricular outflow tract gradient (LVOTG), ejection fraction, volumes, septum thickness, and left atrial fractional shortening (LAFS) were evaluated on echocardiography.
RESULTS: [123I]-MIBG WOR showed a positive relationship with LVOTG (r=0.84, p<0.001) and septum thickness (r=0.76, p<0.01), while a negative one was found with LAFS (r= -0.66, p<0.05). The study group was divided into: Group A (n=5) with higher, and Group B (n=6) with lower WOR than the median value (i.e. 11%). Group A patients had significantly lower LAFS (17.6+/-4.8 vs 26.8+/-7.2%, p<0.05), higher LVOTG (49+/-35 vs 3+/-3 mmHg), and thicker septum (21+/-2 vs 17+/-2 mm) than Group B patients. Inferior and septal wall [123I]-MIBG uptake on 4 hour SPET was significantly lower in Group A than in Group B. On the other hand, no differences were found in (99m)T-MIBI SPET rest regional uptake between the 2 subgroups of patients.
CONCLUSION: These results suggest that cardiac sympathetic activity correlates to cardiac anatomy (i.e. degree of hypertrophy) and diastolic function in patients with HCM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15195000

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  6 in total

Review 1.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

2.  Simultaneous Tc-99m/I-123 dual-radionuclide myocardial perfusion/innervation imaging using Siemens IQ-SPECT with SMARTZOOM collimator.

Authors:  Yong Du; Manojeet Bhattacharya; Eric C Frey
Journal:  Phys Med Biol       Date:  2014-05-13       Impact factor: 3.609

3.  123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders.

Authors:  Susanna Nuvoli; Angela Spanu; Maria Rita Piras; Antonio Nieddu; Aldo Mulas; Gaia Rocchitta; Grazia Galleri; Pier Andrea Serra; Giuseppe Madeddu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

4.  Angiotensin-converting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy.

Authors:  Yumei Feng; Chetan Hans; Elizabeth McIlwain; Kurt J Varner; Eric Lazartigues
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

Review 5.  Cardiac sympathetic activity in hypertrophic cardiomyopathy and Tako-tsubo cardiomyopathy.

Authors:  Derk O Verschure; Berthe L F van Eck-Smit; G Aernout Somsen; Hein J Verberne
Journal:  Clin Transl Imaging       Date:  2015-08-04

6.  Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy.

Authors:  Quirino Ciampi; Iacopo Olivotto; Jesus Peteiro; Maria Grazia D'Alfonso; Fabio Mori; Luigi Tassetti; Alessandra Milazzo; Lorenzo Monserrat; Xusto Fernandez; Attila Pálinkás; Eszter Dalma Pálinkás; Róbert Sepp; Federica Re; Lauro Cortigiani; Milorad Tesic; Ana Djordjevic-Dikic; Branko Beleslin; Mariangela Losi; Grazia Canciello; Sandro Betocchi; Luis Rocha Lopes; Ines Cruz; Carlos Cotrim; Marco A R Torres; Clarissa C A Bellagamba; Caroline M Van De Heyning; Albert Varga; Gergely Ágoston; Bruno Villari; Valentina Lorenzoni; Clara Carpeggiani; Eugenio Picano
Journal:  J Clin Med       Date:  2021-03-24       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.